CompletedPhase 3

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

United States12,301 participantsStarted 2019-06-11

Plain-language summary

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event.

Who can participate

Age range50 Years – 79 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓.Diagnostic evidence of at least one of the following (A-D) at screening:
✓. percutaneous coronary intervention (PCI) of 2 or more vessels, including branch arteries,
✓. PCI or coronary artery bypass grafting (CABG) with residual 50% stenosis in a separate, unrevascularized vessel, or
✓. multi-vessel CABG 5 years or more prior to screening.
✓≥65 years of age.

What they're measuring

Time to Coronary Heart Disease Death, Myocardial Infarction, or Ischemic Stroke

Timeframe: From randomization; for approximately a median of 4.5 years

Time to Coronary Heart Disease Death, Myocardial Infarction, Ischemic Stroke, or Any Ischemia-driven Arterial Stroke

Timeframe: From randomization; for approximately a median of 4.5 years

Trial details

NCT IDNCT03872401

SponsorAmgen

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-07-25

View on ClinicalTrials.gov More Coronary Heart Disease (CHD) trials